(UroToday.com) Dr. Christoph Wurnschimmel discussed long-term validation on the impact of PSMA-PET on metastasis-free survival (MFS) in a large salvage radiotherapy cohort at the European Association of Urology (EAU) 2021 annual meeting’s detection of recurrence and salvage treatment options after primary treatment of prostate cancer session. Earlier studies focusing on the impact of PSMA-PET imaging for treatment planning prior to salvage radiotherapy for PSA recurrence after radical prostatectomy suggested a high response rate in PSMA negative findings as opposed to PSMA positive findings. However, most available literature either only reported short-term follow-up or did not address long-term MFS. The objective of this study was to provide a large and contemporary report that provides 5-year MFS rates after salvage radiotherapy by PSMA PET results.